Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
about
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzymeUse of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysisAntioxidant-based therapies for angiotensin II-associated cardiovascular diseasesStructural Insights into Central Hypertension Regulation by Human Aminopeptidase AThe inextricable role of the kidney in hypertensionAngiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research DatabaseAT1A angiotensin receptors in the renal proximal tubule regulate blood pressure.Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells.Dynamic changes in the secondary structure of ECE-1 and XCE account for their different substrate specificities.Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines.Dual blockade of the renin-angiotensin system in diabetic nephropathy.Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry.Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: challenges in comparative effectiveness using Medicare data.Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.Zofenopril and incidence of cough: a review of published and unpublished data.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Effectiveness, safety and cost of drug substitution in hypertensionThe effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial.Drug-induced visceral angioedema.Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.The impact of Medicare Part D on medication treatment of hypertension.The potential economic impact of restricted access to angiotensin-receptor blockersThe value of irbesartan in the management of hypertension.Antihypertensive agents in hemodialysis patients: a current perspective.Hypertension management in patients with chronic kidney disease.The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years oldReappraisal of role of angiotensin receptor blockers in cardiovascular protectionRole of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study resultsShort- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utilityInhibition of RAS in diabetic nephropathy.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskThe impact of comparative effectiveness research on health and health care spending.Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials.The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimentaSources of regional variation in Medicare Part D drug spending.Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines.
P2860
Q24306614-5D1A2E67-B820-403E-9105-2B298839B7E5Q24646726-70C4C9F3-F0D0-4A87-A0D2-CC5B13FC0179Q27016563-5AC66787-7EF6-40C5-8EBF-19BFBAAF1037Q27679202-789F8C9D-B134-4FD4-BCEF-8D8FC86C7F64Q28241252-9E178050-FA9F-40DD-9D25-A47806097751Q28730234-CB6A0421-425C-404E-8B9D-2E14B72C2245Q30427451-5416C58C-19B8-4353-95DA-0A6924830E96Q30441613-A6D690AF-B532-4C69-97FB-4597CA8893A5Q31106005-C941B31A-0235-46D7-8B74-69620D5B0E39Q33360298-B6B1F328-5404-43FB-A116-213D91A5B927Q33610694-91C5B2FF-4AB8-4C1B-9CAC-93C98682D4E4Q33730477-67548B2B-4541-4B29-92DF-D097B0851459Q33804032-256C7776-50DB-4DD3-992F-E622775513F9Q33858023-7822D563-EA89-4CC2-A2F5-9A055ACC7760Q33867082-26CC6354-C720-47C5-A2AE-DEE130C34BDDQ34056044-AC9F5AA2-A8CB-46C7-AFE3-419E0AFF695CQ34093100-32DAE3D3-2E80-43EB-851D-A7CA2AE0A474Q34097737-132B2B84-54B8-48F2-8A2C-66F1535C339AQ34142036-0BE7D37F-D047-454E-80F7-6E2DF801380AQ34174844-1A52FF7B-81F9-4707-A903-CA1EB721E138Q34286911-D18D1A79-BD00-44F5-BAF7-0684C1941F78Q34288820-FF170685-09D2-4E90-B619-E115D0011FD8Q34546377-5815062F-9FCB-489A-B0F4-E2F48EDE9D37Q34554697-BFAEA43F-F0BA-4881-942C-F0A0884F9E8BQ34590001-2F111142-34B0-4DD4-AAF0-C16B9F2784A2Q34609900-EEF2940B-2522-44FC-97BF-006A5F5EC2A2Q34700870-4321BF15-DC7B-4018-BF6B-BD8493EE3867Q34822390-02B31E6C-18AC-49F0-A8F3-9F3FD6772FBCQ34978490-A5242C2E-8BD6-4F01-8166-0808C4D84432Q35015215-C1D2A123-6B45-4B46-95F6-6BBF9A94798BQ35115546-97F43542-E6FD-4310-9246-6E8BEF59D8B9Q35210549-99C87C15-E059-4B7F-B48C-690CB3B849CCQ35210583-0AE1E983-45B3-42EF-90B9-758DB318BA79Q35491275-435F45D8-B364-4E91-8095-3EB761F9B560Q35539305-CCEEA05A-70D8-4598-AE8D-2555837F816DQ35622994-580E1394-CB8C-4730-9500-6B54A8AC9810Q35684200-7895E339-21F5-4004-B264-9FB1F0D45C54Q35770269-4FDD41E9-981C-4DD9-B65B-B5961CC3322CQ35773656-C4501B5B-F009-4294-89B2-788274B375BEQ36137337-0FCB2ABD-B098-4200-9660-1156D89C3930
P2860
Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systematic review: comparative ...... eating essential hypertension.
@en
type
label
Systematic review: comparative ...... eating essential hypertension.
@en
prefLabel
Systematic review: comparative ...... eating essential hypertension.
@en
P2093
P1476
Systematic review: comparative ...... eating essential hypertension.
@en
P2093
Benjamin Powers
David B Matchar
Douglas C McCrory
Gregory P Samsa
Lori A Orlando
Manesh R Patel
Meenal B Patwardhan
Rebecca N Gray
Uptal D Patel
P356
10.7326/0003-4819-148-1-200801010-00189
P407
P577
2007-11-05T00:00:00Z